Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Abuse-Deterrent Formulations of Purdue's OxyContin and Endo Pharmaceuticals' Opana ER Have Not Increased PCPs' Comfort When



 Abuse-Deterrent Formulations of Purdue's OxyContin and Endo Pharmaceuticals'
Opana ER Have Not Increased PCPs' Comfort When Prescribing These Products for
                                 Chronic Pain

More Than Half of Surveyed MCO Directors Report That Coverage of OxyContin and
Opana ER Has Not Changed with the Availability of Abuse-Deterrent
Formulations, According to a New Report from Decision Resources

PR Newswire

BURLINGTON, Mass., July 16, 2013

BURLINGTON, Mass., July 16, 2013 /PRNewswire/ -- Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that despite the replacement of Purdue Pharma's
OxyContin and Endo Pharmaceuticals' Opana ER with abuse-deterrent
formulations, surveyed primary care physicians (PCPs) do not feel more
comfortable prescribing these products for the treatment of chronic pain. In
contrast, the majority of surveyed pain specialists report that they are more
comfortable prescribing OxyContin and Opana ER now that the products feature
abuse-deterrent properties.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The U.S. Physician & Payer Forum report entitled Chronic Pain: How Will U.S.
Payers and Prescribers Shape Market Access for Recently Launched and Emerging
Products? also finds that 57 percent and 53 percent of surveyed managed care
organization (MCO) directors report that coverage of OxyContin and Opana ER
has not changed as a result of the products' reformulation to be
abuse-deterrent—suggesting that, in many patients, the cost to reimburse
OxyContin and Opana ER may outweigh the advantages of the abuse-deterrent
formulations. In cases where a non-abuse-deterrent generic opioid was
available, MCO directors are likely to only reimburse an abuse-deterrent
product in patients with a history of drug abuse—signaling that emerging
abuse-deterrent formulations will still be subject to coverage restrictions.

The report also finds that cost will likewise be an important consideration
for prescribing and reimbursement of new chronic pain therapies, most notably
for Pfizer's novel anti-NGF therapy tanezumab. Seventy-four percent of
surveyed PCPs and 48 percent of surveyed pain specialists who do not expect to
prescribe tanezumab cite the high expected cost of the drug for the patient as
a reason that they would be unwilling to prescribe the drug. As a biologic
therapy, tanezumab is expected to be priced at a considerable premium over
traditional oral analgesics.

"Although the responses of surveyed physicians suggest that efficacy and
safety/tolerability are the most important factors influencing treatment
decisions for chronic pain, these physicians anticipate that patient
out-of-pocket costs and reimbursement constraints will directly influence
their prescribing of emerging chronic pain therapies," said Decision Resources
Principal Business Insights Analyst Natalie Taylor, Ph.D. "Even if an emerging
therapy demonstrates significantly greater efficacy than the current standard
of care for reducing pain, we find that both surveyed PCPs and pain
specialists consistently assign lower anticipated patient shares to emerging
therapies if the agents were to be covered by MCOs as non-preferred brands.
However, emerging therapies that lower the overall long-term costs of treating
chronic pain conditions may potentially secure more favorable reimbursement
status from MCOs."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com. 

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Website: http://decisionresourcesgroup.com
Contact: Decision Resources, Christopher Comfort, 781-993-2597,
ccomfort@dresources.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement